A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 05 Oct 2016 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.
- 05 Oct 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 05 Oct 2016 Status changed from not yet recruiting to recruiting.